Drug intelligence / Profile preview

risperidone + vitamin B12

Development stage: Preclinical
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

A therapeutic combination of risperidone, an atypical antipsychotic medication, and vitamin B12 (cyanocobalamin). This combination has been studied for its potential benefits in treating psychotic symptoms, particularly in Alzheimer's disease patients. Research suggests that vitamin B12 supplementation alongside antipsychotic drugs like risperidone may help reduce proinflammatory cytokines and increase anti-inflammatory cytokines, potentially improving psychotic symptoms. Additionally, vitamin B12 may help address some side effects associated with antipsychotic treatment.

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on risperidone + vitamin B12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone + vitamin B12.

Explore the full profile